Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease

NCT06612268 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06612268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06612268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Recruiting
Start date
February 17, 2025
Completion date
August 12, 2029
Enrollment
510 (estimated)
Sites
175

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease